Faisal A, Basit A, Iftikhar A, Saifullah M, Rehmaan MKU, Basil AM. Lepodisiran: From genetic targeting to cardiovascular promise: A detailed narrative review of the literature. World J Cardiol 2025; 17(8): 109657 [PMID: 40949934 DOI: 10.4330/wjc.v17.i8.109657]
Corresponding Author of This Article
Abdul M Basil, MD, Doctor, Department of Medicine, Spinghar Medical University, 4th Alley, Char Rahe Qambar Kabul, Kabul 1001, Afghanistan. abdulmaboodbasil@outlook.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Aug 26, 2025 (publication date) through Nov 4, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Faisal A, Basit A, Iftikhar A, Saifullah M, Rehmaan MKU, Basil AM. Lepodisiran: From genetic targeting to cardiovascular promise: A detailed narrative review of the literature. World J Cardiol 2025; 17(8): 109657 [PMID: 40949934 DOI: 10.4330/wjc.v17.i8.109657]
World J Cardiol. Aug 26, 2025; 17(8): 109657 Published online Aug 26, 2025. doi: 10.4330/wjc.v17.i8.109657
Lepodisiran: From genetic targeting to cardiovascular promise: A detailed narrative review of the literature
Affan Faisal, Abdul Basit, Abdullah Iftikhar, Muneeb Saifullah, M Khalil ur Rehmaan, Abdul M Basil
Affan Faisal, Abdul Basit, Abdullah Iftikhar, Muneeb Saifullah, Department of Medicine, King Edward Medical University, Lahore 54000, Punjab, Pakistan
M Khalil ur Rehmaan, Department of Medicine, Sialkot Medical College, Sialkot 51040, Punjab, Pakistan
Abdul M Basil, Department of Medicine, Spinghar Medical University, Kabul 1001, Afghanistan
Author contributions: Faisal A and Basit A gave study conception; Basit A, Faisal A, Iftikhar A, Saifullah M and Rehman MKU wrote the manuscript; Basil AM supervised the study; All the authors proofread the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abdul M Basil, MD, Doctor, Department of Medicine, Spinghar Medical University, 4th Alley, Char Rahe Qambar Kabul, Kabul 1001, Afghanistan. abdulmaboodbasil@outlook.com
Received: May 19, 2025 Revised: June 14, 2025 Accepted: August 4, 2025 Published online: August 26, 2025 Processing time: 96 Days and 12.4 Hours
Abstract
Elevated lipoprotein(a) [Lp(a)] is a major independent risk factor for atherosclerotic cardiovascular disease (ASCVD), with limited response to traditional lipid-lowering therapies. Lepodisiran, a novel N-acetylgalactosamine-conjugated small interfering RNA, targets hepatic LPA message RNA to reduce apolipoprotein(a) production. Early-phase trials demonstrated > 90% sustained Lp(a) reduction with excellent safety and tolerability. The phase 2 ALPACA trial confirmed durable effects lasting up to one year after biannual dosing. Compared to other therapies, lepodisiran offers longer duration, high efficacy, and minimal side effects. Ongoing phase 3 studies aim to determine its impact on cardiovascular outcomes, potentially establishing a new standard in precise ASCVD risk management.
Core Tip: Lepodisiran is a novel N-acetylgalactosamine-conjugated small interfering RNA that durably reduces lipoprotein(a) [Lp(a)] levels by silencing hepatic LPA message RNA expression. It offers up to 94% sustained Lp(a) reduction with minimal side effects and extended dosing intervals (6-12 months). This therapeutic breakthrough addresses a key residual cardiovascular risk factor previously untreatable with conventional lipid-lowering agents.
